Back to News
Market Impact: 0.18
Standigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AI
Source: PR Newswire
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Protai and Standigm announced a Korea-Israel collaboration, supported by KORIL-RDF, combining AI-powered structural proteomics with generative drug-design technology. The partnership targets improved selectivity in targeted protein degradation, a key technical challenge in developing precision therapeutics; no financial terms, development milestones, or commercial outlook were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- 'Hostile act': Trump threatens EU with tariffs over Canada associate-membership proposal
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Fed delivers its first hike in 3 years. Plus, what's moving Starbucks and GE Vernova
- Fed’s Warsh lays out forces driving up bond yields
- The Fed unanimously agrees to hike interest rates for the first time since 2023, despite Trump’s call for the ‘lowest rates’ in the world
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction
- What Is an AI Investment Research Platform?